Category Archives: Clostridioides difficile Infection

Making a Difference – Innovations in Infection Prevention 2020 Awards

Awards Announcement:

Making a Difference – Innovations in Infection Prevention 2020

C Diff Foundation acknowledges the following organizations “Making a Difference”
In the Infection Prevention community, with their innovative products, services, and
technologies addressing infection prevention.

 

 

 

 

Applied Silver
Innovation: SilvaClean® Technology
SilvaClean chemistry is EPA-approved as a laundry additive with residual activity
against post-laundry contamination.
The SilvaClean system is a dispensing device enabled by the Internet of Things (IoT)
that doses the EPA-approved SilvaClean chemistry onto textiles, leaving fabrics with
residual antimicrobial properties even after laundering (e.g. in storage, during handling
and in use).
http://www.appliedsilver.com/

 

 

 

 

Intellego Technologies
Innovation: UVC Dosimeter™
Able to measure specific wavelengths of UVC radiation.
Can be correlated with a log reduction of microbiology samples e.g. MRSA and C. diff.
Proven functionality through hospital testing.
http://intellego-technologies.com/

 

 

 

 

Synexis Biodefense Systems
Innovation: Synexis™ Microorganism Reduction Systems
Patented Dry Hydrogen Peroxide (DHP) technology uses a building’s ambient humidity
and oxygen to continuously achieve sustainable reduction of microbial challenges from
viruses, bacteria, and mold in the air and on workplace surfaces.
DHP technology is inexpensive, highly scalable, and can be installed standalone or in
existing HVAC systems.
https://synexis.com/

Join Us in November!

Join Us at the 8th Annual International C. diff. Conference and Health EXPO taking
place in Boston, Massachusetts USA on November 12th and 13th, 2020 where we will
present and showcase these prestigious awards to the 2020 “Making a Difference” Innovations In Infection Prevention organizations.

Early Bird Registration is in progress — save over 20% until June 2020.

Congratulations to the organizations dedicated in preventing infections and for
developing products, services, and technology capable to ward off harmful bacteria in
all areas of health care and commercial environments. We are truly grateful for the
innovative measures taken to accomplish this goal.

 

 

C Diff Foundation, a 501(c) (3) non-profit organization, established in 2012, and
comprised of 100% volunteering professionals dedicated at supporting public health
through education and advocating for C. difficile infection (CDI) prevention, treatments,
clinical trials, diagnostics, and environmental safety worldwide.

 

(Disclaimer: C Diff Foundation declares no conflict of interest; no funds or influence
were provided to C Diff Foundation by any parties.)

 

C Diff Foundation Announces Appointment of Paul Feuerstadt, M.D., Director of Medical Education

C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, “It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press.”

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, EverythingCdifficile.com. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: “Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in
the C.diff. community. Dr. Feuerstadt’s new role as Director of Medical Education will provide an additional avenue of support to patients, families, caregivers, and healthcare providers  through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt’s time and dedication as we continue fighting this debilitating disease worldwide.”

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

 

 

Study Finds C.diff. Infections Could Be Reduced by 13% In Hospital Transfers

“We defined a patient transfer as a patient discharged from one hospital and then admitted to another hospital on the same day.”

The study findings reinforce that infection prevention and control strategies should be conducted at the regional level to better minimize the spread of HAIs, Sewell and colleagues said.

Study findings showed that hospital transfers cause a “minority but substantial burden” of Clostridioides difficile infections in California and that the burden could be reduced by 13% statewide if contamination from hospital transfers was eliminated.

Hospital transfers are known to be associated with the spread of pathogens like C. difficile and MRSA, but researchers said it is critical to better understand the role that hospital transfers play in the spread of hospital-acquired infections, or HAIs.

“The relationship between hospital transfers and higher levels of HAIs is unclear, as is the public health significance of this relationship,” Daniel K. Sewell, PhD, assistant professor of biostatistics in the University of Iowa College of Public Health, and colleagues wrote.

They conducted a retrospective observational study using data collected between 2005 and 2011 from the Healthcare Cost and Utilization Project California State Inpatient Database.

“We were able to discern transfers between hospitals by considering patients who had common discharge and admission dates involving two distinct hospitals,” Sewell and colleagues wrote. “We defined a patient transfer as a patient discharged from one hospital and then admitted to another hospital on the same day.”

According to the study, Sewell and colleagues identified 26,878,498 admissions and 532,925 patient transfers across 385 hospitals. They found that 13% of C. difficile infections (CDIs) were a result of patient transfers (95% CI, 7.6%-18%). Additionally, the researchers observed CDI cases increase at receiving hospitals when the number of transfer patients increased or when the CDI rate at the transferring hospital increased, or both.

“Transfers of patients demonstrate the interconnectedness of health care systems,” they wrote. “Accordingly, efforts to control the spread of infections at one facility may benefit others, and the less rigorous infection control efforts at some hospitals may impact the infection rates at other hospitals within a transfer network.” – by Marley Ghizzone

 

 

 

 

To review article in its entirety please click on the following link to be redirected:

 

https://www.healio.com/infectious-disease/nosocomial-infections/news/online/%7B7bc8ae6c-fcc3-4ca6-a625-29301eb6535a%7D/eliminating-contamination-from-hospital-transfers-could-reduce-cdi-cases-by-13

First Time Clostridioides difficile Infection Study Reveals Correlation Between Antibiotic Use and CDI Utilizing Data From 2006-2012

ABSTRACT :   Association between Antibiotic Use and Hospital-Onset Clostridioides difficile Infection in U.S. Acute Care Hospitals, 2006-2012: an Ecologic Analysis

“> Sophia V Kazakova, M.D., M.P.H, Ph.D James Baggs, Ph.D L Clifford McDonald, M.D Sarah H Yi, Ph.D Kelly M Hatfield, M.S.P.H Alice Guh, M.D., M.P.H Sujan C Reddy, M.D., M.Sc John A Jernigan, M.D., M.S

Clinical Infectious Diseases, ciz169, https://doi.org/10.1093/cid/ciz169
Published:
01 March 2019
Article history

Abstract

Background

Unnecessary antibiotic use (AU) contributes to increased rates of Clostridioides difficile Infection (CDI). The impact of antibiotic restriction on hospital-onset CDI (HO-CDI) has not been assessed in a large group of U.S. acute care hospitals (ACHs).

Methods

We examined cross-sectional and temporal associations between rates of hospital-level AU and HO-CDI using data from 549 ACHs. HO-CDI, a discharge with a secondary ICD-9-CM for CDI (008.45) and treatment with metronidazole or oral vancomycin ≥ 3 days after admission. Analyses were performed using multivariable generalized estimating equation models adjusting for patient and hospital characteristics.

Results

During 2006-2012, the unadjusted annual rates of HO-CDI and total AU were 7.3 per 10,000 patient-days (PD) (95% CI: 7.1-7.5) and 811 days of therapy (DOT)/1,000 PD (95% CI: 803-820), respectively. In the cross-sectional analysis, for every 50 DOT/1,000 PD increase in total AU, there was a 4.4% increase in HO-CDI.

For every 10 DOT/1,000 PD increase in use of third- and fourth-generation cephalosporins or carbapenems there was a 2.1% and 2.9% increase in HO-CDI, respectively. In the time-series analysis, the 6 ACHs with a ≥ 30% decrease in total AU had a 33% decrease in HO-CDI (rate ratio, 0.67; 95% CI, 0.47-0.96); ACHs with a ≥ 20% decrease in fluoroquinolone or third- and fourth-generation cephalosporin use had a corresponding decrease in HO-CDI of 8% and 13%, respectively.

Conclusions

At an ecologic level, reductions in total AU, use of fluoroquinolones and third- and fourth-generation cephalosporins were each associated with decreased HO-CDI rates.

To review Abstract in .pdf and in its entirety please click on the following link to be redirected.

Thank you.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz169/5367464?fbclid=IwAR0S6XfRWoKTJNmBoZLQicy2BqzuOOyRF9dx2ctQGRn0K9K0m79cr7Or7pQ